GSK taps Angiochem to take enzymes across blood-brain barrier
This article was originally published in Scrip
GlaxoSmithKline is stepping up its activity in the rare disease area, signing an early-stage deal that may yield a breakthrough in treatments for lysosomal storage disorders (LSDs). It is offering Angiochem of Canada upwards of $300 million if it can help it develop blood-brain barrier (BBB)-crossing enzyme replacement therapies which could for the first time address the CNS symptoms of such diseases. The deal will see Angiochem, which specialises in getting drugs through the BBB, bring at least one product up to the point of IND notification for GSK's rare diseases unit to take on for clinical development and commercialisation.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.